Continues to make progress toward Biologics License Application (BLA) submission for EB-101 in late-2Q/early-3Q 2023; submitted request for pre-BLA meeting...…
Advancing AAV-based gene therapy candidates toward IND studies on encouraging animal proof of concept data in Stargardt Disease, X-linked Retinoschisis…
CHAPEL HILL, North Carolina--(BUSINESS WIRE)--Areteia Therapeutics, Inc. („Areteia“) gab heute bekannt, dass sich das Unternehmen auf der 42. jährlichen J.P.…